NTU-developed COVID-19 nasal spray vaccine may soon enter human trials

A new type of COVID-19 nasal spray vaccine Taiwan's researchers are developing have shown more effective than the traditional shot in animal trials, and has a chance to enter human trials in the first half of 2022, a research team from National Taiwan University (NTU) said Wednesday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)